SETD2 and nonpapillary renal cell carcinoma: Consistent with previous studies based on the immunotherapy effectiveness in ccRCC (28, 29), we found that the mutation frequencies of SETD2 and BAP1 were higher and their expression were both downregulated in the high-risk group.